Dendritic Polypeptide Nanocarriers for Multi-Agent Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nanotechnology-based drug delivery systems face challenges in effectively delivering multiple therapeutic agents simultaneously to cancer cells, particularly for aggressive diseases like brain and breast cancers, due to limitations in targeting specificity and synergistic therapeutic effects.
Innovation Solution
Development of dendritic polypeptide-based nanocarriers with a core atom and multiple arms containing cysteines, lysines, and histidines, which allow for the covalent conjugation and controlled delivery of anticancer drugs and siRNAs, enhancing solubility, cellular uptake, and endosomal escape.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional nanocarriers (dendrimers, liposomes, metallic nanoparticles) are used for drug delivery, then targeted delivery and bioavailability are improved, but the ability to deliver multiple therapeutic agents simultaneously is limited
Solution Approach 1:
The nanocarrier is divided into multiple functional segments: a core structure for stability, multiple arms for agent attachment, and specific functional groups (cysteines, lysines, histidines) for different types of therapeutic agents. This segmentation allows simultaneous loading of multiple drugs and siRNAs with distinct properties.
Solution Approach 2:
The dendritic polypeptide nanocarrier is designed as a universal platform that can accommodate multiple types of therapeutic agents (small molecule drugs, siRNAs, proteins) through its diverse functional groups. The multiple arms with different amino acid residues provide universal binding capabilities for various agents.
2Reliability
If nanocarriers are designed for targeted delivery, then site-specific delivery is improved, but solubility and stability of therapeutic agents may worsen
Solution Approach 1:
The nanocarrier combines multiple materials at the molecular level: polypeptide backbone providing biocompatibility and solubility, cysteine residues for drug conjugation, lysine residues for siRNA complexation, and histidine residues for pH-responsive behavior. This composite structure achieves both solubility and targeted delivery.
Solution Approach 2:
The nanocarrier utilizes pH parameter changes to achieve targeted delivery: histidine residues undergo protonation at acidic pH (tumor microenvironment and endosomes), triggering conformational changes that promote endosomal escape and controlled drug release, while maintaining stability at physiological pH.
3Productivity
If multiple therapeutic agents are loaded into nanocarriers, then synergistic therapeutic effect is improved, but the complexity of the delivery system increases
Solution Approach 1:
The nanocarrier architecture segments different therapeutic agents onto separate arms, allowing independent loading and controlled release of each agent while maintaining overall system simplicity through modular design.
Solution Approach 2:
The invention merges multiple therapeutic agents (drugs and siRNAs) into a single nanocarrier platform, achieving synergistic effects while simplifying the delivery process compared to separate administration of multiple therapies.
4Stability of the object's composition
If dendritic polypeptide structure is used for covalent conjugation, then controlled release and solubility are improved, but manufacturing precision requirements increase
Solution Approach 1:
The dendritic polypeptide structure enables self-assembly and spontaneous conjugation of therapeutic agents through inherent chemical reactivity of functional groups (thiol-disulfide exchange, amine-carboxyl coupling), reducing the need for precise external control during manufacturing.
Solution Approach 2:
The conjugation process utilizes pH parameter changes to control drug release: acid-labile linkages remain stable at physiological pH but cleave at acidic pH, providing controlled release without requiring complex manufacturing precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dendritic polypeptide-based delivery system achieves a synergistic inhibition of cancer cell proliferation by efficiently loading and releasing multiple drugs and siRNAs, demonstrating enhanced therapeutic efficacy and biocompatibility, with improved solubility and controlled release mechanisms.
Implementation Method 1
The plurality of amino acids comprises a plurality of cysteines, a plurality of lysines, and a plurality of histidines
Implementation Method 2
The plurality of amino acids comprises a plurality of cysteines, a plurality of lysines, and a plurality of histidines
Data Source
AI summary
Dendritic polypeptides useful for the delivery of therapeutic agents into cells are disclosed, together with their methods of preparation. These dendritic polypeptides serve as carriers of drugs, siRNA, aptamers and plasmid DNA in the treatment of various diseases, including cancer.